BioTech
Will Geron be acquired? The long-short view
This is the online edition of Adam’s Biotech Scorecard, a subscriber-only newsletter. STAT+ subscribers can sign up here to get it delivered every Thursday to their inbox.
I’m back from my ASCO-Chicago detour. I missed you all!
This week, let’s argue over Geron’s future and consider Candel Therapeutics to illustrate why survival claims from non-randomized studies are too often red flags. I sound like a biotech nerd. I guess I am.